FDA authorizes first test for Patient At-Home Collection Sample

  • The US Food and Drug Administration (FDA) authorizes the first diagnostic test with a home-collection option for COVID-19.
  • FDA reissued the emergency use authorization (EUA) for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test to permit testing of samples self-collected by patients at home using LabCorp’s Pixel by LabCorp COVID-19 Test home collection kit.
  • Patients can collect sample from their nose by using a designated self-collection kit that contain nasal swabs and saline. After collecting their nasal sample, they mail their sample in an insulated package, to a LabCorp lab for testing.
  • The LabCorp home self-collection kit includes a specific Q-tip-style cotton swab which can be used by patients to collect their sample. Due to concerns with sterility and cross-reactivity due to inherent genetic material in cotton swabs, other cotton swabs should not be used with this test at the present time.
  • LabCorp intends to make home collection kits available to most of costumers in coming weeks.
  • This authorization only applies to the LabCorp COVID-19 RT-PCR Test for at-home collection of nasal swab specimens using the Pixel by LabCorp COVID-19 home collection kit. It is important to note that this is not a general authorization for at-home collection of patient samples using other collection swabs, media, or tests, or for tests fully conducted at home.

For more information, please visit the cited source.

Reference

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-patient-home-sample-collection